Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Executive Summary
Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.
You may also be interested in...
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
The XenoMouse That Roared: Cell Genesys' Share Of Abgenix Worth $781 Mil.
Cell Genesys' 12% share of Abgenix at the end of February is worth more than twice the value of Genzyme's attempted acquisition of Cell Genesys in October.
Ilex Finds Comfortable Niche As Wall Street Attitude Towards CROs Sours
Ilex Oncology's combination of contract research and a proprietary pipeline is finding favor on Wall Street as the CRO industry overall weathers a slump.